23 Aug 2006 - Alnylam Pharmaceuticals, Inc. has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, an InterfeRx(TM) license to discover, develop, and commercialize an RNAi therapeutic utilizing a synthetic siRNA, together exclusively with Calando's proprietary delivery technology, that is directed towards a cancer target. As part of the agreement, Calando also has an option to acquire an InterfeRx license for a second target gene. Detailed financial terms were not disclosed, but include upfront, annual, and milestone payments, and royalties on sales of any products covered by the licensing agreement.
 |
www.bionity.com/news/e/57272 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/57272 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |